Reuters logo
BRIEF-Geneuro signs agreement with NIH to develop antibody treatment for ALS
February 7, 2017 / 5:37 PM / 10 months ago

BRIEF-Geneuro signs agreement with NIH to develop antibody treatment for ALS

Feb 7 (Reuters) - Geneuro SA:

* Signs cooperative research and development agreement (CRADA) with National Institutes of Health (NIH) to develop novel antibody treatment for amyotrophic lateral sclerosis (ALS) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below